Allstate Corp Acquires 47,838 Shares of Gilead Sciences, Inc. $GILD

Allstate Corp raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 105.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 93,103 shares of the biopharmaceutical company’s stock after buying an additional 47,838 shares during the quarter. Allstate Corp’s holdings in Gilead Sciences were worth $11,427,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its position in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after acquiring an additional 1,618,453 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Gilead Sciences by 1.0% in the 4th quarter. Legal & General Group Plc now owns 10,317,613 shares of the biopharmaceutical company’s stock worth $1,266,384,000 after acquiring an additional 107,014 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Gilead Sciences by 5.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after acquiring an additional 400,002 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of Gilead Sciences by 16.5% in the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after acquiring an additional 726,101 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock opened at $134.36 on Tuesday. The company has a market capitalization of $166.82 billion, a PE ratio of 18.31 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The firm’s 50-day moving average is $136.05 and its 200 day moving average is $133.81. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on GILD shares. Deutsche Bank Aktiengesellschaft raised their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Rothschild & Co Redburn lowered their target price on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Daiwa Securities Group lowered their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Weiss Ratings upgraded shares of Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, May 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Monday, February 23rd. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $156.93.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead completed its $3.15 billion acquisition of Tubulis GmbH, adding a new antibody-drug conjugate platform that should strengthen its oncology pipeline and broaden growth opportunities. Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio
• Positive Sentiment: Gilead received an FDA approval for Hepcludex, the first U.S. treatment for chronic hepatitis delta, while Europe’s CHMP backed Trodelvy for triple-negative breast cancer, reinforcing the company’s near-term commercial and pipeline momentum. GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
• Positive Sentiment: Maxim upgraded Gilead Sciences to Buy, adding to the view that the shares remain attractive at current levels and are supported by dividend income and a solid franchise. Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’
• Positive Sentiment: Brokerage coverage remains supportive overall, with Gilead carrying an average “Moderate Buy” rating, which can help underpin investor sentiment. Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Articles discussing stocks trading below estimated fair value are broad market pieces and do not provide a specific company-specific catalyst for Gilead. Three Stocks That May Be Trading Below Their Estimated Value In May 2026
• Neutral Sentiment: Another “top stocks trading below fair value” market roundup is similarly general and not a direct catalyst for GILD. May 2026’s Top Stocks That Could Be Trading Below Estimated Fair Value

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares in the company, valued at $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer directly owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,000 shares of company stock worth $8,523,570 over the last three months. 0.30% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.